---
figid: PMC3808235__zlj9991032880001
figtitle: Pathway-guided treatment in prostate cancer
organisms:
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3808235
filename: zlj9991032880001.jpg
figlink: /pmc/articles/PMC3808235/figure/F1/
number: F1
caption: Pathway-guided treatment in prostate cancer. This diagram highlights pathways
  for targeting in prostate cancer, including the phosphatidylinositide 3-kinase (PI3K)
  pathway, ETS rearrangements, and androgen signaling. Green indicates putative treatment
  hypotheses for relevant pathways. Each of these pathways can be driven by genomic
  aberrations, such as point mutations, copy number alterations, and rearrangements.
  The diagram also highlights less common driving mutations involving RAS, RAF, and
  AKT oncogenes. Furthermore, there is potential for cooperation between pathways
  because these are not necessarily mutually exclusive. Genes highlighted in gold
  have known genomic alterations. AR, androgen receptor; mTOR, mammalian target of
  rapamycin, PARP, poly (ADP-ribose) polymerase; RTK, receptor tyrosine kinase.
papertitle: Advancing Precision Medicine for Prostate Cancer Through Genomics.
reftext: Sameek Roychowdhury, et al. J Clin Oncol. 2013 May 20;31(15):1866-1873.
year: '2013'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9282957
figid_alias: PMC3808235__F1
figtype: Figure
redirect_from: /figures/PMC3808235__F1
ndex: 4d986a25-df0b-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3808235__zlj9991032880001.html
  '@type': Dataset
  description: Pathway-guided treatment in prostate cancer. This diagram highlights
    pathways for targeting in prostate cancer, including the phosphatidylinositide
    3-kinase (PI3K) pathway, ETS rearrangements, and androgen signaling. Green indicates
    putative treatment hypotheses for relevant pathways. Each of these pathways can
    be driven by genomic aberrations, such as point mutations, copy number alterations,
    and rearrangements. The diagram also highlights less common driving mutations
    involving RAS, RAF, and AKT oncogenes. Furthermore, there is potential for cooperation
    between pathways because these are not necessarily mutually exclusive. Genes highlighted
    in gold have known genomic alterations. AR, androgen receptor; mTOR, mammalian
    target of rapamycin, PARP, poly (ADP-ribose) polymerase; RTK, receptor tyrosine
    kinase.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - PTEN
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - AR
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - PRKDC
  - AURKA
  - ETS1
  - ETS2
  - Tie
  - Ras85D
  - InR
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - ras
  - Ras64B
  - Pten
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - rl
  - ar
  - Parp
  - aurA
  - Ets21C
  - Ets65A
  - pnt
  - Ets96B
  - Ets97D
  - Ets98B
  - Androgen
  - Testosterone
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
